Evidence map›Paper›PMID 35534765›Full record

ArticleJournal of natural medicines2022

Refined-JinQi-JiangTang tablet ameliorates hypertension through activation of FGF21/FGFR1 axis in fructose-fed rats.

Siming Li, Xiaoling Li, Jing Fan, Xinhang Jia, Hemeng Wang, Fangxin Dong, Haoyang Mao, Chen Zhang, Wenfei Wang, Ye Jiang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Fibroblast growth factor 21 in metabolic syndrome.Frontiers in endocrinology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Siming LiSchool of Pharmacy, Harbin University of Commerce, Harbin, 150076, China.ORCID http://orcid.org/0000-0001-8750-687X
Xiaoling LiSchool of Pharmacy, Harbin University of Commerce, Harbin, 150076, China.
Jing FanCollege of Food Engineering, Harbin University of Commerce, Harbin, 150076, China.
Xinhang JiaSchool of Pharmacy, Harbin University of Commerce, Harbin, 150076, China.
Hemeng WangCollege of Life Sciences, Northeast Agricultural University, Harbin, 150006, China.
Fangxin DongSchool of Pharmacy, Harbin University of Commerce, Harbin, 150076, China.
Haoyang MaoSchool of Pharmacy, Harbin University of Commerce, Harbin, 150076, China.
Chen ZhangSchool of Pharmacy, Harbin University of Commerce, Harbin, 150076, China.
Wenfei WangCollege of Life Sciences, Northeast Agricultural University, Harbin, 150006, China.
Ye JiangCollege of Life Sciences, Northeast Agricultural University, Harbin, 150006, China.
Lijun YanSchool of Pharmacy, Harbin University of Commerce, Harbin, 150076, China. ylj@hrbcu.edu.cn.
Na ZhangCollege of Food Engineering, Harbin University of Commerce, Harbin, 150076, China. foodzhangna2021@163.com.
Harbin University of Commerce · CNNortheast Agricultural University · CN

Funding

National Natural Science Foundation of China 81903787Natural Science Foundation of Heilongjiang Province YQ2021H002
6 · The paper itself

Abstract

The aim of this study was to investigate the therapeutic effect of JQ-R on metabolic hypertension and its correlation with Fibroblast growth factor 21/Fibroblast growth factor receptors 1(FGF21/FGFR1) pathway. In this study, fructose-induced metabolic hypertension rats were used as hypertension models to detect the regulation effect of JQ-R on hypertension. The effects of JQ-R on blood glucose, blood lipids, serum insulin levels and other metabolic indicators of rats were also measured. The effects of JQ-R on FGF21/FGFR1 signaling pathway in model animals were detected by Real-time quantitative PCR and Western blotting. The results showed that JQ-R significantly reduce the blood pressure of model rats in a dose-dependent manner. Meanwhile, fasting insulin, fasting blood glucose, insulin resistance index, total cholesterol and triglyceride levels were significantly decreased, and glucose and lipid metabolism abnormalities were also significantly improved. JQ-R induces these changes along with FGFR1 phosphorylation, which was also detected in JQ-R treated FGF21 knockout mice. These results suggest that JQ-R can reduce blood pressure and improve glucose and lipid metabolism in fructose-induced hypertension rats. Activation of FGF21/FGFR1 signaling pathway to regulate downstream blood pressure and glucolipid metabolism-related pathways may be one of the important mechanisms of JQ-R in regulating blood pressure.

Indexed as

FructoseHypertensionAnimalsDrugs, Chinese HerbalFibroblast Growth FactorsGlucoseInsulinMiceRatsReceptor, Fibroblast Growth Factor, Type 1TabletsDrugs, Chinese Herbalfibroblast growth factor 21Fibroblast Growth FactorsFructoseGlucoseInsulinJinqiReceptor, Fibroblast Growth Factor, Type 1TabletsACE2AktFGF21/FGFR1 axisMetabolic hypertensionRefined-JinQi-JiangTang tablets (JQ-R)

Identifiers

PMID35534765
OpenAlexW4229443394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.